Aisling Capital related stories
All articles and analysis
IPO Window Opens UpWith some recent IPOs, such as Groupon, some are saying the market for VC-backed public offerings is starting to rebound
After Jubilant Spring, Summer Turns Rocky for IPOsStill, 2011 is on pace to outdo last year’s IPO tally
- Steven Elms Joins Pernix Board
Steven Elms, a managing partner at private equity firm Aisling Capital, has joined the board of publicly traded pharmaceutical company Pernix Therapeutics Holdings Inc. Previously, Elms was a senior member of the Life Sciences Investment Banking Group of Hambrecht & Quist. Penix Therapeutics is focused on the sales, marketing and development of branded and generic drugs primarily for the pediatric market.
- T2 Biosystems Seals $23M Series D
Lexington, Mass.-based T2 Biosystems has closed a $23 million Series D financing round led by new investor Aisling Capital. Return backers Flagship Ventures, Polaris Venture Partners, Flybridge Capital Partners, Physic Ventures, Partners Healthcare, Arcus Ventures, RA Capital, Camros Capital and WS Investments also contributed. The money will help with ongoing development and clinical trials of the company’s diagnostic technology.